

Special Issue

Advances in Surgical Management of Ovarian Cancer

Message from the Guest Editor

This Special Issue, “*Advances in Surgical Management of Ovarian Cancer*”, will present a comprehensive overview of evolving surgical strategies and their impact on patient care. It will highlight innovations in cytoreductive techniques, minimally invasive approaches, and the integration of hyperthermic intraperitoneal chemotherapy (HIPEC). A key focus will be on perioperative outcomes, including morbidity, recovery metrics, and quality-of-life indicators, which are critical in optimizing surgical decision-making and enhancing patient-centered care. This Special Issue will also explore multidisciplinary collaboration, surgical planning in advanced and recurrent disease, and the role of precision medicine in tailoring operative interventions. By bringing together leading voices in gynecologic oncology, this Special Issue will inform clinical practice, guide future research, and improve both short- and long-term outcomes for patients undergoing surgery for ovarian cancer. Keywords:

- ovarian cancer
- surgical management
- complications
- HIPEC
- survival

Guest Editor

Dr. Lina Salman

1. Department of Obstetrics and Gynecology, Queen's University, Kingston, ON K7L 3N6, Canada
2. Division of Gynecologic Oncology, Durham Regional Cancer Centre, Lakeridge Health Hospital Ct, Oshawa, ON L1G 8A2, Canada

Deadline for manuscript submissions

30 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/252130

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)